NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...
Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...
Positive allosteric modulators (PAMs) of the muscarinic acetylcholine M4 receptor show potential against schizophrenia because they can enhance endogenous acetylcholine signaling, which in turn may ...
Neuphoria Therapeutics Inc.’s phase III study of social anxiety disorder has missed its primary and secondary endpoints, ...
Long interspersed nuclear element-1 (LINE-1 or L1) is the only active, self-copying genetic element in the human ...
The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback